In 2023, the global contrast media injectors market reached a value of USD 1.27 billion and is expected to expand at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2030. This market growth is primarily driven by the increasing prevalence of chronic disorders, advancements in medical technology, and rising demand for minimally invasive surgeries. The surge in chronic diseases has amplified the need for diagnostic imaging tests, which utilize both traditional methods like X-rays and ultrasounds and advanced techniques such as CT scans and MRIs. These imaging tests are crucial for diagnosing various conditions, informing surgical or interventional treatments, and conducting perioperative imaging before surgery. The growing incidence of chronic diseases and complex co-morbidities has thus become a key factor driving demand in the contrast media injectors market.

Furthermore, rapid technological advancements, higher healthcare spending, and improvements in patient care quality are fueling a global rise in demand for minimally invasive surgical procedures. Contrast media injectors are vital for surgeons as they allow precise administration of contrast agents, reducing human errors and enhancing accuracy and efficiency in operations. These injectors are particularly important in fields like interventional radiology and cardiology. The availability of advanced injection systems for both diagnostic and intraoperative imaging is expected to further boost adoption rates.

Gather more insights about the market drivers, restrains and growth of the Global Contrast Media Injectors Market

The COVID-19 pandemic initially impacted the contrast media injectors market, as many radiology departments experienced a decline in imaging case volumes, resulting in lower demand. However, post-pandemic recovery efforts have seen organizations optimize their supply chains to reduce product costs and enhance the quality and service associated with contrast media injectors. By minimizing reliance on third parties, these strategies have unlocked new growth opportunities for the market.

Minimally invasive surgeries (MIS) offer numerous advantages, such as faster recovery times, smaller incisions, reduced infection risk, minimal scarring, shorter hospital stays, and reduced blood loss. These benefits are expected to drive market expansion during the forecast period. Additionally, MIS procedures performed with contrast media injectors enable real-time, high-quality imaging, offering significant precision for surgical and diagnostic purposes. The increase in regulatory approvals for contrast media injectors, particularly by agencies like the U.S. FDA and the EU, is also projected to contribute to market growth.

End-use Insights

In 2023, the hospital segment dominated the market with a revenue share of 68.37% and is expected to grow at the highest CAGR from 2024 to 2030. This growth is attributed to the rising number of hospital admissions for conditions like neurological disorders, cardiovascular diseases, and cancer. Hospitals are the primary users of contrast media injectors due to their extensive applications across radiology, interventional radiology, and interventional cardiology. For instance, the American Hospital Association reported 6,120 hospitals in the U.S. in 2022. The ongoing development of healthcare infrastructure in emerging countries is also expected to boost the market in the coming years.

The diagnostic centers segment is anticipated to grow at a significant CAGR over the forecast period. This growth is driven by the rise in private imaging centers, spurred by the increased demand for diagnostic imaging, the importance of early diagnosis, and limited imaging facilities in smaller hospitals. The expansion of diagnostic centers addresses this demand and supports market growth.

Order a free sample PDF of the Contrast Media Injectors Market Intelligence Study, published by Grand View Research.